117 related articles for article (PubMed ID: 22459565)
1. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma.
Decaens T; Luciani A; Itti E; Hulin A; Roudot-Thoraval F; Laurent A; Zafrani ES; Mallat A; Duvoux C
Dig Liver Dis; 2012 Jul; 44(7):610-6. PubMed ID: 22459565
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
Di Costanzo GG; Tortora R; Iodice L; Lanza AG; Lampasi F; Tartaglione MT; Picciotto FP; Mattera S; De Luca M
Dig Liver Dis; 2012 Sep; 44(9):788-92. PubMed ID: 22579445
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response.
Yeo W; Chan SL; Mo FK; Chu CM; Hui JW; Tong JH; Chan AW; Koh J; Hui EP; Loong H; Lee K; Li L; Ma B; To KF; Yu SC
BMC Cancer; 2015 May; 15():395. PubMed ID: 25962426
[TBL] [Abstract][Full Text] [Related]
5. Pilot study: rapamycin in advanced hepatocellular carcinoma.
Schöniger-Hekele M; Müller C
Aliment Pharmacol Ther; 2010 Sep; 32(6):763-8. PubMed ID: 20629977
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
Choo SP; Chowbay B; Ng QS; Thng CH; Lim C; Hartono S; Koh TS; Huynh H; Poon D; Ang MK; Chang S; Toh HC
Eur J Cancer; 2013 Mar; 49(5):999-1008. PubMed ID: 23265712
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I
Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Kondo M; Morimoto M; Numata K; Nozaki A; Tanaka K
Jpn J Clin Oncol; 2011 Jan; 41(1):69-75. PubMed ID: 20688778
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Shen C; Peng C; Shen B; Zhu Z; Xu N; Li T; Xie J
Oncotarget; 2016 Sep; 7(38):62647-62656. PubMed ID: 27577068
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Weinmann A; Niederle IM; Koch S; Hoppe-Lotichius M; Heise M; Düber C; Schuchmann M; Otto G; Galle PR; Wörns MA
Dig Liver Dis; 2012 May; 44(5):432-7. PubMed ID: 22265328
[TBL] [Abstract][Full Text] [Related]
13. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.
Rizell M; Andersson M; Cahlin C; Hafström L; Olausson M; Lindnér P
Int J Clin Oncol; 2008 Feb; 13(1):66-70. PubMed ID: 18307022
[TBL] [Abstract][Full Text] [Related]
14. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
16. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).
Tinker AV; Ellard S; Welch S; Moens F; Allo G; Tsao MS; Squire J; Tu D; Eisenhauer EA; MacKay H
Gynecol Oncol; 2013 Aug; 130(2):269-74. PubMed ID: 23672928
[TBL] [Abstract][Full Text] [Related]
19. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
[TBL] [Abstract][Full Text] [Related]
20. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]